最新刊期
卷 32 ， 期 3 ， 2022
- 摘要：Background and purpose: Serine/arginine-rich splicing factor 1 (SRSF1) is closely related to the development of tumor. Esophageal carcinoma is the common malignant tumor of digestive system. However, the role of SRSF1 in esophageal carcinoma is rarely reported. This study aimed to detect the expression of SRSF1 in esophageal squamous cell carcinoma (ESCC) and its effects on the proliferation, invasion and migration of ESCC cells, and to explore its mechanism. Methods: Forty pairs of ESCC tissues and paracancerous tissues resected at the Fourth Hospital of Hebei Medical University from January 2020 to December 2021 were collected for this study. The expression of SRSF1 in ESCC was detected by immunohistochemistry. The mRNA expression and protein level of SRSF1 in ESCC cells were detected by real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) and Western blot, respectively. Eca9706 cell with high expression of SRSF1 was selected. The mRNA expression of SRSF1 was reduced by small interfering RNA (siRNA). The proliferation, migration and invasion of Eca9706 cells were detected by cell counting kit-8 (CCK-8), transwell and Matrigel matrix gel assays, respectively. Database was used to analyze the expression of vascular endothelial growth factor A (VEGFA) in ESCC tissues, and the correlation between expressions of SRSF1 and VEGFA was also analyzed. RTFQ-PCR was used to detect the expression levels of VEGFA Iso8a and Iso8b isoform in Eca9706 cells, and the change in VEGFA Iso8a and Iso8b isoform expressions was also detected after knocking down SRSF1. Results: The expression of SRSF1 was significantly higher in ESCC tissues than in normal esophageal tissues (P<0.05). SRSF1 mRNA and protein were highly expressed in Eca9706 cells (both P<0.01). The mRNA expression and protein level of SRSF1 was significantly lower in siRNA-SRSF1 group than in siRNA-NC group (P<0.01). After knocking down SRSF1, the proliferation, migration and invasion abilities of Eca9706 cells were significantly lower compared with siRNA-NC group (all P<0.05). The expression of VEGFA was significantly higher in ESCC tissue than in normal esophageal tissue (P<0.05), and it was positively correlated with the expression of SRSF1 (P<0.01). RTFQ-PCR showed that the level of VEGFA Iso8a expression in Eca9706 cells was significantly higher compared with VEGFA Iso8b (P<0.01). Moreover, the level of VEGFA Iso8a expression was significantly decreased, while the level of VEGFA Iso8b expression increased after knocking down SRSF1 (P<0.01). Conclusion: SRSF1 can promote proliferation, invasion and migration of ESCC Eca9706 cells by possibly regulating VEGFA mRNA splicing.关键词：Esophageal squamous cell carcinoma;Serine/arginine-rich splicing factor 1;Vascular endothelial growth factor A;Cell proliferation;Cell migration;Cell invasion2064|1976|0更新时间：2025-12-31
- 摘要：Background and purpose: Traditional preparation of subcutaneous transplanted tumor of prostate cancer relies on cell suspension injection. However, there are great limitations. The purpose of this study was to explore the feasibility of developing a new animal model of subcutaneous transplanted prostate cancer with cell sheet technology. Methods: Human prostate cancer DU145 cells were inoculated into a 35 mm temperature sensitive cell culture dish, and the prostate cancer cell sheet was prepared by continuous culture and identified by H-E staining and immunohistochemistry. According to the research purpose, cell suspension group and cell membrane group were set up. DU145 cell suspension was subcutaneously injected into nude mice in cell suspension group, and DU145 cell sheet was subcutaneously injected into BALB/c nude mice in cell sheet group. The BALB/c nude mice were sacrificed 4 weeks after transplantation, and the grafted tumors in both groups were dissected for further histological analysis, including collagen fiber content, local infiltration and angiogenesis. Meanwhile, the common organs of prostate cancer metastasis, such as bone, lung and liver, were dissected to evaluate the systemic metastasis in both groups. Results: DU145 prostate cancer cell sheet could be prepared at 1 week after continuous culture. Histological staining revealed a membrane structure with an average thickness of (32.6±7.5) μm. The DU145 cell sheet was rich in collagen fibrin with high vimentin expression and low E-cadherin expression. H-E staining showed that the tumor structure was dense with obvious infiltration of surrounding muscles in the cell sheet group, while the tumor had more vacuoles and a clear boundary with surrounding tissues in the cell suspension group 4 weeks after subcutaneous transplantation. Moreover, the transplanted tumor volume was significantly higher in the cell sheet group than in the cell suspension group, and the measured tumor volume in the two groups were (0.967±0.129) and (0.437±0.054) cm3 (t = 3.774, P = 0.019 5), respectively. Masson staining showed that the content of blue collagen fiber was significantly higher in the cell sheet group than in the cell suspension group, and the optical densities (D) value of the two groups were 0.023 0±0.001 1 and 0.014 0±0.000 7 (t = 7.022, P = 0.000 1), respectively. Immunohistochemical staining of CD31 showed that the microvascular density per ×200 field in the cell sheet group and the cell suspension group were 53.20±3.56 and 32.40±4.98 (t = 3.392, P = 0.009 5), respectively. Gross anatomy and H-E staining showed no obvious systemic metastasis in the two groups 4 weeks after subcutaneous transplantation. Conclusion: It is feasible and advantageous to develop the animal model of subcutaneous transplanted prostate cancer using cell sheet technology. Compared with traditional cell suspension injection method, the tumor volum was larger, the infiltration degree was deeper with surrounding tissues, the density of new microvessels was higher, and the collagen content was richer, which is more helpful to reveal the real biological characteristics of prostate cancer. It is expected to be applied in the research of molecular genetics of prostate cancer, drug resistance mechanism and drug discovery.关键词：Cell sheet technology;Prostate cancer model;Ectopic implantation;Tumor microenvironment115|1511|0更新时间：2025-12-31
- 摘要：Background and purpose: Golgi membrane protein 1 (GOLM1) plays the role of an oncogene in lung adenocarcinoma (LUAD), however, the effects of GOLM1 on the proliferation, invasion and migration of LUAD cells and its mechanism are not clear yet. This study investigated the effects of GOLM1 on the proliferation, invasion and migration of LUAD cells and its mechanism of action. Methods: We selected cancer tissues and corresponding paracancerous tissue specimens from 90 LUAD patients who underwent surgical resection in Karamay Central Hospital from April 2019 to April 2021. The expression of GOLM1 protein in LUAD tissues and paracancerous tissues was detected by immunohistochemistry, and the relationship between GOLM1 protein expression and clinicopathological characteristics of LUAD tissues was analyzed. Western blot was used to detect the expression of GOLM1 protein in human lung epithelial cells BEAS-2B and human lung adenocarcinoma H460, A549, PG49 and H1299 cells. Lung adenocarcinoma A549 cells in logarithmic growth stage were randomly divided into blank group (cells not transfected), GOLM1 small interfering RNA negative control (si-NC) group (cells transfected with si-NC), GOLM1 small interfering RNA (si-GOLM1) group (cells transfected with si-GOLM1), insulin-like growth factor-1 (IGF-1) group [10 μmol/L phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway activator IGF-1 for 30 min] and si-GOLM1+IGF-1 group (after treatment with 10 μmol/L IGF-1 for 30 min, si-GOLM1 was transfected). Cell counting kit-8 method was used to detect cell proliferation in each group of lung adenocarcinoma A549 cells. Scratch test was used to detect cell migration in each group of lung adenocarcinoma A549 cells. Transwell experiment was used to detect cell invasion in each group of lung adenocarcinoma A549 cells. Western blot was used to detect the expressions of GOLM1 and PI3K/AKT/mTOR signaling pathway related proteins in each group of lung adenocarcinoma A549 cells. Xenograft model was constructed by subcutaneously injecting A549 cells on the right side of BALB/c nude mice, which were divided into: nude mice blank group, nude mice si-NC group, nude mice si-GOLM1 group, nude mice IGF-1 group, nude mice si-GOLM1+IGF-1 group, with 6 mice in each group. The nude mice were sacrificed six weeks after injection, the tumor was collected, and the weight and volume of the tumor were measured. Results: The results of immunohistochemistry showed that the positive expression rate of GOLM1 protein was significantly higher in LUAD tissues than in adjacent tissues (P<0.05). The expression of GOLM1 protein was significantly correlated with the degree of tumor differentiation, lymph node metastasis, and clinical stage (P<0.05), but not significantly correlated with gender, age and smoking status of LUAD patients (P>0.05). Compared with BEAS-2B cells, the relative expression level of GOLM1 protein in human lung adenocarcinoma H460, A549, PG49 and H1299 cells was significantly increased (P<0.05), and the relative expression level of GOLM1 protein in A549 cells was the highest. Therefore, A549 cells were selected for subsequent experiments. Compared with the blank group and the si-NC group, OD value, scratch healing rate, number of invaded cells, GOLM1, p-PI3K/PI3K, p-AKT/AKT and p-mTOR/mTOR protein relative expression levels in the lung adenocarcinoma A549 cells of the si-GOLM1 group were significantly reduced (P<0.05). In the lung adenocarcinoma A549 cells of the IGF-1 group, there was no significant change in GOLM1 protein, and the other corresponding indicators were significantly increased (P<0.05). Compared with the si-GOLM1 group, the OD value, scratch healing rate, number of invaded cells, p-PI3K/PI3K, p-AKT/AKT and p-mTOR/mTOR protein relative expression levels of lung adenocarcinoma A549 cells in the si-GOLM1+IGF-1 group were significantly increased (P<0.05), and there was no significant difference in GOLM1 protein relative expression level (P>0.05). Compared with the nude mice blank group and nude mice si-NC group, the mass and volume of transplanted tumors in the nude mice si-GOLM1 group were significantly reduced, while the mass and volume of transplanted tumors in the nude mice IGF-1 group were significantly increased (P<0.05). Compared with the nude mice si-GOLM1 group, the mass and volume of transplanted tumors in the nude mice si-GOLM1+IGF-1 group were significantly increased (P<0.05). Conclusion: Silencing GOLM1 gene can inhibit the activation of PI3K/AKT/mTOR signaling pathway, thereby inhibiting the proliferation, migration and invasion of lung adenocarcinoma A549 cells.关键词：Golgi membrane protein 1;Lung adenocarcinoma;Cell proliferation;Cell invasion;Cell migration;Phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway366|1514|0更新时间：2025-12-31
- 摘要：Background and purpose: N6-methyladenosine (m6A) methylation modification recognition protein YTHDF2 has been shown to play an important role in cancer progression. This research was designed to explore whether YTHDF2 regulated cell cycle and apoptosis of glioblastoma (GBM) via promoting mRNA decay of insulin-like growth factor binding protein 7 (IGFBP7) and activating phosphoinositide 3-kinase (PI3K)-protein kinase (AKT) signaling pathway. Methods: The expressions of YTHDF2 and IGFBP7 in GBM tissues and cells were detected by real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR). The cell cycle and apoptosis rate were detected by flow cytometry. Protein expressions of p-AKT, AKT, p-PI3K and PI3K were detected by Western blot. RNA immunoprecipitation (RIP) assay and RNA stability experiment were used to verify the relationship between YTHDF2and IGFBP7. Results: Compared with adjacent tissues and normal astrocyte line (NHA cells) expression of YTHDF2 was increased while expression of IGFBP7 was decreased in GBM tissues and cells (all P<0.05). Knockdown of YTHDF2 could induce GBM cell cycle arrest and increase apoptotic rate (P<0.05). In GBM cells, YTHDF2 could induce IGFBP7 mRNA decay via recognizing m6A modified IGFBP7 (P<0.05). Inhibition of IGFBP7 partially rescued the effects of si-YTHDF2 on GBM cell cycle and apoptosis (all P<0.05). In addition, YTHDF2 promoted the malignant progression of GBM by regulating IGFBP7 to activate PI3K/AKT signaling pathway (P<0.05). Conclusion: YTHDF2 promotes the malignant biological behavior of GBM cells through regulating IGFBP7 expression by means of m6A modification and activating PI3K/AKT signaling pathway.关键词：YTHDF2;Glioblastoma;Cell cycle;Cell apoptosis91|1413|0更新时间：2025-12-31
- 摘要：Background and purpose: The incidence of ductal carcinoma in situ (DCIS) has increased annually with the popularity of mammography screening. However, current treatment strategies are mostly based on the results of prospective randomized clinical trials in western countries. This study aimed to explore the clinical characteristics, recurrence patterns and prognostic factors of Chinese DCIS patients, hoping to optimize clinical decision-making. Methods: Medical records of 1 185 DCIS patients treated in Fudan University Shanghai Cancer Center from January 2008 to January 2017 were retrospectively analyzed. The local recurrence-free survival (LRFS) rate, disease-free survival (DFS) rate and overall survival (OS) rate were calculated using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the COX proportional hazards regression model. Results: With a median follow-up of 61 months, 50 treatment failure events were observed, including 16 locoregional recurrences, 30 contralateral breast cancer events and 4 distant metastases. The 5-year OS rate, LRFS rate and DFS rate were 99.9%, 98.7% and 96.6%, respectively. In the multivariate analysis, the positive status of human epidermal growth factor receptor 2 (HER2) was related to higher risk of local recurrence and the LRFS rate was poor (P=0.029). Conclusion: The patient with DCIS was associated with favorable prognosis. HER2 positivity was the risk factor for poor LRFS.关键词：Ductal carcinoma in situ;Breast cancer;Prognosis61|1165|0更新时间：2025-12-31
- 摘要：Background and purpose: Spindle cell melanoma (SCM) is a rare type of melanoma with few studies on its survival prognosis. The nomogram for predicting 5- and 10-year cancer-specific survival (CSS) and overall survival (OS) of patients with cutaneous SCM was constructed and validated by extracting SCM clinical information from a public database. Methods: A total of 1 445 patients were screened from the Surveillance, Epidemiology, and End Results (SEER) database and divided into training cohort (n=1 011) and validation cohort (n=434). The nomogram was constructed based on these independent prognostic factors which were determined by univariate and multivariate COX regression analyses. The concordance index (C-index), receiver operating characteristic (ROC) curve and calibration curve were used to evaluate the discrimination and accuracy of the nomogram. Decision curve analysis (DCA) was used to evaluate the clinical utility of the model. Results: Age, tumor site, thickness, ulceration, N stage, M stage and surgery were included in the prediction model. The C-index of the nomogram was 0.778 (CSS) and 0.753 (OS) in the training cohort, and 0.749 (CSS) and 0.712 (OS) in the validation cohort, respectively. The area under curve (AUC) of 5- and 10-year CSS were 0.815 and the AUC of 5- and 10-year OS were 0.825, and the AUC of 5- and 10-year OS were 0.803 and 0.825 in the training cohort, respectively. The AUC of 5- and 10-year were 0.777 and 0.836, and 0.754 and 0.799 in the validation cohort, respectively. The calibration curve fitted well with the 45° line. DCA showed that the nomogram had the clinical net benefit in a wide range of threshold probabilities and had good clinical application value. Conclusion: The nomogram had good predictive ability and clinical application value for the prognosis of SCM patients.关键词：Spindle cell melanoma;Nomogram;Cancer-specific survival;Overall survival;Prognosis29|1434|0更新时间：2025-12-31
- 摘要：Background and purpose: Colorectal cancer is one of the most common malignant tumors of digestive system. The incidence of colorectal cancer has increased significantly in China in recent years. Various clinical and pathological indicators are helpful for the diagnosis, clinical staging and prognostic evaluation of colorectal cancer. This study aimed to observe the correlation between the expression of mismatch repair protein and serum tumor markers and Ki-67 proliferation index in colorectal cancer, and to analyze the prognostic value of mismatch repair protein, serum tumor markers and Ki-67 proliferation index. Methods: Data of 234 patients with colorectal cancer were collected after surgery in Huadong Hospital Affiliated to Fudan University from July 2014 to June 2018, and the preoperative serum levels of tumor markers (CEA, CA19-9, CA72-4, CA12-5), Ki-67 proliferation index and mismatch repair protein expression rate in surgical specimens were analyzed, in order to find the relationship between these clinicopathological features and prognosis of colorectal cancer. Results: Among 234 postoperative specimens of colorectal cancer patients, a total of 29 cases (12.4%) had defective expression of mismatch repair protein (dMMR), and 205 cases (87.6%) had normal expression of mismatch repair protein (pMMR). In the correlation analysis of clinicopathological features, there were statistically significant differences in tumor primary site, differentiation type, stage, T stage and lymph node metastasis between dMMR group and pMMR group (P<0.05). In the correlation analysis of the observed indicators, the differences in Ki-67 proliferation index, preoperative CEA and CA72-4 levels between dMMR group and pMMR group were statistically significant (P<0.05). Among the univariate prognostic analyses, the overall survival rate was significantly lower in the lymph node metastasis group and the advanced stage group (P<0.001). There was significant difference in overall survival rate between dMMR group (100%) and pMMR group (83%) (P<0.05). In the prognostic analysis of the preoperative tumor markers, CEA and CA72-4 levels had prognostic value in survival analysis (P<0.05). Multivariate COX regression analysis of 5 variables showed no significant correlation between expression of mismatch repair protein and lymph node metastasis in prognostic analysis, while significant correlation between staging and preoperative CA72-4 level was found in prognostic analysis (P<0.05). It was suggested that staging and preoperative CA72-4 level were the most important risk factors affecting the prognosis of colorectal cancer patients. Conclusion: dMMR was more common in right-sided colon cancer and in poorly differentiated adenocarcinoma and mucinous adenocarcinoma with poor type. T stage was late, while general pathological stage was early. Lymph node metastasis was rare. In dMMR group, Ki-67 proliferation index was mostly below the mean level (<70% expression), most patients had normal preoperative CEA level and elevated preoperative CA72-4 level. The dMMR group had a higher survival rate compared with the pMMR group, and later stage and increased preoperative CA72-4 level were risk factors affecting prognosis of patients. The expression deficiency of mismatch repair protein has certain prognostic value in patients with colorectal cancer.关键词：Mismatch repair protein;Serum tumor marker;Ki-67 proliferation index;Colorectal cancer;Prognosis54|1943|0更新时间：2025-12-31
- 摘要：Background and purpose: There are many anastomoses between stomach and esophagus in esophageal cancer surgery, each of which has its own advantages and disadvantages. The aim of this study was to investigate the safety and feasibility of end-to-end double-layer esophagogastric anastomosis and gastric fundus embedding during minimally invasive esophagectomy for esophageal cancer. Methods: The clinicopathological data of 129 patients who underwent minimally invasive esophagectomy from April 2019 to April 2021 in Zigong Fourth People’s Hospital were retrospectively reviewed. All patients were treated with thoracoscopy and laparoscopy combined with minimally invasive cervicothoracic and abdominal tri-incision (McKeown procedure) esophageal cancer resection. The thoracic procedure was performed with thoracoscopy, and the abdominal procedure with laparoscopy. The patients were divided into end-to-end double-layer esophagogastric anastomosis and gastric fundus embedding group (87 cases) and end-to-side anastomosis group (42 cases). Patients were followed up for evaluation of associated complications, of which anastomotic leakage, anastomotic stenosis and gastroesophageal reflux were the primary objectives of this study. Results: All the 129 patients underwent esophagectomy. Neoadjuvant therapy was more common in the end-to-end doubled anastomosis group (12.0% vs 2.3%, P = 0.037). There was no statistically significant difference in other basic clinical data between the two groups (P>0.05). There was no significant difference in the mean operation time between the two groups. The anastomosis time was less in end-to-side stapling group than in end-to-end stapling group[(32.0±6.8) min vs (15.0±5.4) min, P = 0.021]. The differences in the incidences of anastomotic leakage (1.1% vs 11.9%, P = 0.023), gastroesophageal reflux (9.1% vs 26.1%, P = 0.012), pneumonia (12.6% vs 30.9%, P = 0.023) and arrhythmia (10.3% vs 26.1.%, P = 0.020) were statistically significant between the two groups. Conclusion: The method of end-to-end double-layer anastomosis and gastric fundus embedding is safe and stable in esophagectomy. It can effectively prevent anastomotic leakage and gastroesophageal reflux.关键词：Esophageal cancer;Esophagectomy;Hand-sewn anastomosis;End-to-end clouble-layer esophagogastric anastomosis;Gastric fundus embedding25|1064|0更新时间：2025-12-31
Article
- 摘要：Epstein-Barr virus (EBV) can be latent in resting memory or naive B lymphocytes for a long time in affected people. Aging-induced immunosenescence is associated with an increased risk of EBV-related malignancies in EBV-infected patients. EBV positive diffuse large B-cell lymphoma, not otherwise specified (EBV+DLBCL-NOS) is identified as occurring in large B-cell lymphoma with no known history of immunodeficiency disease or lymphoma and whose tumor nuclei expressed EBV encoded RNA (EBER). The prevalence of EBV+DLBCL-NOS is significantly higher in Asia and Latin America than in other regions worldwide, and it mainly affects patients aged 50 years or older. EBV+DLBCL-NOS patients are associated with a more aggressive clinical course, a more advanced disease, and a higher rate of extra-nodal involvement (more than 80%) compared with EBV negative DLBCL (EBV-DLBCL) patients. The elderly patients with EBV+DLBCL-NOS have poorer overall survival and progression-free survival than young adults. Rituximab-containing immunochemotherapy significantly improves the prognosis of patients with EBV-DLBCL, however, the optimal first-line treatment for EBV+DLBCL-NOS still needs to be further explored. The current understanding of EBV+DLBCL-NOS, a rare subtype of DLBCL, is very limited because of the relatively low incidence of EBV+DLBCL-NOS with a regional difference, as well as lacking high-quality clinical study. However, the DLBCL field is changing rapidly with new technologies, such as next-generation sequencing. To date, few studies have reported that multiple cells signaling pathways are aberrantly activated in tumor cells of EBV+DLBCL-NOS, such as nuclear factor-κB (NF-κB) and Janus kinase/signal transducer and activator of transcription (JAK/STAT). In addition, abnormalities in immune processes have been observed in tumor cells of EBV+DLBCL-NOS, such as the response to interferon, the antigen presentation system, and immune checkpoint molecules. The discovery of these basic research findings fosters the identification of relevant therapeutic targets and facilitates the exploration of novel therapeutic strategies. In the future, the benefits of immunotherapy, targeted therapy, and chimeric antigen receptor T-cell (CAR-T) therapy for EBV+DLBCL-NOS patients remain unknown and require extensive research.关键词：Epstein-Barr virus;Non-Hodgkin’s lymphoma;Diffuse large B-cell lymphoma;Immunotherapy;Targeted therapy2998|4651|0更新时间：2025-12-31
- 摘要：Pancreatic cancer is a malignant tumor with high incidence, rapid progression and low survival rate. It is in urgent need of new targets for precise treatment or improvement of prognosis. In recent years, it has been found that trophoblast cell surface antigen 2 (TROP2) is highly expressed in a variety of malignant tumors and participates in the progress of proliferation, migration and adhesion of malignant tumor cells through cell surface receptor signals. In this paper, the expression of TROP2 in pancreatic cancer, the signaling pathway involved in the mediation of TROP2 and the research progress of antitumor drugs targeting TROP2 were summarized, which provided some references for the mechanism of targeting TROP2 in the treatment of pancreatic cancer and the improvement of prognosis of patients.关键词：Pancreatic cancer;Trophoblast cell surface antigen 2;Targeted therapy;Research progress5110|4289|0更新时间：2025-12-31
Review
- 摘要：The management of bone health in female patients with early breast cancer includes managing bone loss and preventing bone metastasis. As the overall survival of patients with early breast cancer continues to increase, bone health is getting extensive attention. However, there is no specific consensus in China on the methods and strategies of management and treatment. Based on the guideline and the substantial evidence based medicine (EBM), the Society of Breast Cancer of China Anti-Cancer Association and Breast Cancer Study Group Along Yangtze River thoroughly discussed and formulated the Chinese expert consensus recommendations for management of bone health in female patients with early breast cancer (2022 edition), in order to further standardize the management of patient’s bone health.关键词：Breast cancer;Bone health;Cancer treatment-induced bone loss;Bone metastasis21670|1832|0更新时间：2025-12-31
Guideline and Consensus
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
0